Trial site
Xinhua Hospital Affiliated to Shanghai Jiaotong University School of Medicine
- 15running trials
- 4closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Conditions
- Atopic dermatitis (eczema)3 trials
- Childhood cancers2 trials
- Fatty liver disease (MASLD/MASH)2 trials
- Ovarian cancer2 trials
- Alzheimer disease1 trial
- Aortic stenosis1 trial
- Chronic kidney disease1 trial
- Colorectal cancer1 trial
- Coronary artery disease1 trial
- Follicular lymphoma1 trial
- IgA nephropathy1 trial
- Kidney cancer1 trial
- and 4 more
- Phase
- Phase 39 trials
- Phase 23 trials
- Status
- Active, not recruiting8 trials
- Recruiting5 trials
- Completed3 trials
- Enrolling by invitation1 trial
- Not yet recruiting1 trial
- Withdrawn1 trial
- Lead sponsor
- Xinhua Hospital, Shanghai Jiao Tong University School of Medicine5 trials
- Eli Lilly and Company2 trials
- Pfizer2 trials
- Alebund Pharmaceuticals1 trial
- Amgen1 trial
- and 8 more
Running trials
Recruiting
A Study of SHR-1819 Injection in Adolescents With Severe Atopic Dermatitis
Recruiting
Recruiting
Recruiting
Active, not recruiting
Trial of CS060380 Tablets for Non-alcoholic Steatohepatitis (NASH)
Active, not recruiting
Enrolling by invitation
Active, not recruiting
Multi-parametric Ultrasound Versus Multi-parametric MRI for Prostate Cancer Detection
Active, not recruiting
Active, not recruiting
Active, not recruiting
Active, not recruiting
Recruiting
CtDNA as a Novel Biomarker of Treatment Efficacy in Patients With Ovarian Cancer
Active, not recruiting
Recruiting
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
- Atopic dermatitis (eczema)2 recruiting
- Childhood cancers1 recruiting
- Fatty liver disease (MASLD/MASH)1 recruiting
- Kidney cancer1 recruiting
- Neuroblastoma1 recruiting
- Ovarian cancer1 recruiting
Closed trials
Completed
AP301 Efficacy and Safety in Chinese Dialysis Patients With Hyperphosphatemia
Withdrawn
Oral Topotecan Combined With Anlotinib in Patients With Platinum-resistant Recurrent Ovarian Cancer
Completed
Clinical Study of HMPL-689 for Relapsed/Refractory Marginal Zone Lymphoma and Follicular Lymphoma
Completed
Site data: ClinicalTrials.govUpdated 17 Nov 2026